Carteolol HCl Ophthalmic Solution Rx
Generic Name and Formulations:
Carteolol HCl 1%; contains benzalkonium chloride.
Indications for Carteolol HCl Ophthalmic Solution:
Open-angle glaucoma. Ocular hypertension.
1 drop in affected eye(s) twice daily. Concomitant pilocarpine and other miotics, and/or epinephrine or dipivefrin, and/or systemically administered carbonic anhydrase inhibitors may be used if needed.
Sinus bradycardia. Greater than 1st-degree AV block. Cardiogenic shock. Overt cardiac failure. Asthma. Severe COPD.
History of cardiac failure or heart block. Discontinue at 1st sign of cardiac failure. Pulmonary impairment. Diabetes (esp. labile). May mask hypoglycemia and hyperthyroidism. May potentiate muscle weakness. Discontinue before general anesthesia. Avoid abrupt cessation. Pregnancy (Cat.C). Nursing mothers.
May potentiate or be potentiated by systemic β-blockers. May potentiate reserpine, hypoglycemics. May antagonize adrenergic psychotropics.
Ocular: transient eye irritation, burning, tearing, conjunctival hyperemia and edema, blurred/cloudy vision, photophobia, decreased night vision, ptosis; rarely: blepharoconjunctivitis, abnormal corneal staining, corneal sensitivity. Systemic: cardiac arrhythmia, heart palpitation, dyspnea, asthenia, headache, dizziness, insomnia, sinusitis, taste perversion.
Formerly known under the brand name Ocupress.
Soln—5mL, 10mL, 15mL
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Encorafenib, Binimetinib Combination Receives FDA Approval for Mutation-Positive Melanoma
- Certain Risk Factors May Decrease Overall Survival in Pediatric B-NHL
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
- Bariatric Surgery Reduced Risk of Some Cancers in Obese Patients
- Bleeding Disorder Treatments: Hemophilia A
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|